2171.HK
CARSGEN-B
HK$18.11
+6.47%
2026-05-29
About CARSGEN-B
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies. Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.
Key Fundamentals
Forward P/E
7.90
EPS (TTM)
HK$-0.21
ROE
-11.2%
Revenue Growth (YoY)
125.8%
Profit Margin
-77.9%
Debt/Equity
7.85
Price/Book
10.79
Beta
0.28
Market Cap
HK$10.33B
Avg Volume (10D)
9.4M
Recent Breakout Signals
No recent breakout signals detected for 2171.HK.
Recent Price Range (60 Days)
60D High
HK$28.60
60D Low
HK$10.87
Avg Volume
6.9M
Latest Close
HK$18.11
Get breakout alerts for 2171.HK
Sign up for Breakout Scanner to receive daily notifications when 2171.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
CARSGEN-B (2171.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2171.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2171.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.